IVERIC bio, Inc. (ISEE)
Upgrades & Downgrades
Latest ISEE news
Why Is Iveric Bio (ISEE) Stock Up 25% Today?
18 November 2022
Against a relatively flat backdrop for the major equity indices, biotechnology firm Iveric Bio (NASDAQ: ISEE ) provided a decisively positive framework, with shares gaining 25% on Friday afternoon. Ye...
IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
5 November 2022
IVERIC bio, Inc. (NASDAQ:ISEE ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Kathy Galante - SVP, IR & Corporate Communications Glenn Sblendorio - CEO & Director P...
Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio
4 November 2022
Apellis reported an unexpected delay for its eye-disease treatment, leading APLS stock to crash as shares of rival Iveric Bio inched higher. The post Apellis Pharma Crashes On Unexpected Delay For Eye...
These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022
17 October 2022
Mid-cap stocks are a good choice for investors who are okay with relatively more volatility to get some extra returns.
Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in...
27 September 2022
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio will present top-line efficacy and safety results from GATHER2, the Company's second Phase 3 clinical trial of Zimura, at AAO 2022.
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study
7 September 2022
IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.
Iveric bio: Further Upside Possible Based On Expanded Opportunities With Zimura
7 September 2022
Positive results achieved in both GATHER1 and GATHER2 studies, whereby Zimura met prespecified primary endpoints of Mean rate of GA growth compared to sham control with statistical significance. NDA f...
Why Is Iveric Bio (ISEE) Stock Up 56% Today?
6 September 2022
Source: Shutterstock / PopTika Iveric Bio (NASDAQ: ISEE ) stock is rising higher on Tuesday after the biopharmaceutical company revealed positive results from a Phase 3 clinical trial. That trial cove...